Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Quantinuum Inc.QNT · Entity 3437 | Director | June 04, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Quantinuum Inc.
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 255,833 |
Ending reported balance
After 2026-06-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-04 · Grant · Acquired 5,833 · Balance 5,833 F1: Represents an award of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock. The RSUs will vest in three equal annual installments beginning on June 5, 2027. Row 2 · 2026-06-05 · Purchase · Acquired 250,000 · Balance 255,833 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock. The RSUs will vest in three equal annual installments beginning on June 5, 2027.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Juno Therapeutics, Inc.
Report date March 05, 2018 · Filed March 07, 2018
Section 16 reporting ended · disclosed 2018-03-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2018-03-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-03-05 · Other · Disposed 100,000 · Balance 3,780 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement and the Offer, each share of common stock of the Company held by the Reporting Person, other than as described in note (3) below, was validly tendered for $87.00 per share in cash, without interest and subject to withholding of taxes. Row 2 · 2018-03-05 · Disposition to issuer · Disposed 3,780 · Balance 0 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement and the Offer, each share of common stock of the Company held by the Reporting Person, other than as described in note (3) below, was validly tendered for $87.00 per share in cash, without interest and subject to withholding of taxes. F3: In accordance with their terms, RSUs held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such RSU and (ii) $87.00. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.36 · Expires 2024-09-14 | Direct | 0 |
Reported balance
After 2018-03-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-03-05 · Disposition to issuer · Disposed 75,000 · Balance 0 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F4: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.00 · Expires 2025-06-11 | Direct | 0 |
Reported balance
After 2018-03-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-03-05 · Disposition to issuer · Disposed 12,000 · Balance 0 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F4: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.40 · Expires 2026-06-16 | Direct | 0 |
Reported balance
After 2018-03-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-03-05 · Disposition to issuer · Disposed 12,000 · Balance 0 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F4: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.29 · Expires 2027-06-15 | Direct | 0 |
Reported balance
After 2018-03-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-03-05 · Disposition to issuer · Disposed 12,000 · Balance 0 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F4: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent.
F2: Pursuant to the terms of the Merger Agreement and the Offer, each share of common stock of the Company held by the Reporting Person, other than as described in note (3) below, was validly tendered for $87.00 per share in cash, without interest and subject to withholding of taxes.
F3: In accordance with their terms, RSUs held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such RSU and (ii) $87.00.
F4: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 8, 2026 20:31 UTC | Quantinuum Inc. QNT · Entity 3437 | PurchaseClass A Common Stock | 250,000 | $60.00 | $15,000,000.00 |
DisclosureSEC source: 0001628280-26-041630 · wk-form4_1780950696.xml · nonDerivative · entry 2 Barron Hal · CIK 0001418677 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 255,833 Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 20:31 UTC | Quantinuum Inc. QNT · Entity 3437 | GrantClass A Common Stock | 5,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-041630 · wk-form4_1780950696.xml · nonDerivative · entry 1 Barron Hal · CIK 0001418677 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,833 F1 · shares: Represents an award of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock. The RSUs will vest in three equal annual installments beginning on June 5, 2027. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 23:14 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 12,000 | $63.71 Strike: $23.29 | $764,520.00 |
DisclosureSEC source: 0001209191-18-017798 · doc4.xml · derivative · entry 6 Barron Hal · CIK 0001418677 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2027-06-15 F1 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F4 · price: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price. F4 · derivative.exercise_date: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 23:14 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 12,000 | $44.60 Strike: $42.40 | $535,200.00 |
DisclosureSEC source: 0001209191-18-017798 · doc4.xml · derivative · entry 5 Barron Hal · CIK 0001418677 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2026-06-16 F1 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F4 · price: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price. F4 · derivative.exercise_date: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 23:14 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 12,000 | $27.00 Strike: $60.00 | $324,000.00 |
DisclosureSEC source: 0001209191-18-017798 · doc4.xml · derivative · entry 4 Barron Hal · CIK 0001418677 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2025-06-11 F1 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F4 · price: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price. F4 · derivative.exercise_date: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 23:14 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 75,000 | $80.64 Strike: $6.36 | $6,048,000.00 |
DisclosureSEC source: 0001209191-18-017798 · doc4.xml · derivative · entry 3 Barron Hal · CIK 0001418677 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2024-09-14 F1 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F4 · price: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price. F4 · derivative.exercise_date: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 23:14 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | Disposition to issuerCommon Stock | 3,780 | $87.00 | $328,860.00 |
DisclosureSEC source: 0001209191-18-017798 · doc4.xml · nonDerivative · entry 2 Barron Hal · CIK 0001418677 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2 · date: Pursuant to the terms of the Merger Agreement and the Offer, each share of common stock of the Company held by the Reporting Person, other than as described in note (3) below, was validly tendered for $87.00 per share in cash, without interest and subject to withholding of taxes. F3 · price: In accordance with their terms, RSUs held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such RSU and (ii) $87.00. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 23:14 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | OtherCommon Stock | 100,000 | $87.00 | $8,700,000.00 |
DisclosureSEC source: 0001209191-18-017798 · doc4.xml · nonDerivative · entry 1 Barron Hal · CIK 0001418677 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,780 F1 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2 · date: Pursuant to the terms of the Merger Agreement and the Offer, each share of common stock of the Company held by the Reporting Person, other than as described in note (3) below, was validly tendered for $87.00 per share in cash, without interest and subject to withholding of taxes. Read SEC document |
| January 05, 2018 Filed Jan 10, 2018 02:02 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | GrantCommon Stock | 336 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-003053 · doc4.xml · nonDerivative · entry 1 Barron Hal · CIK 0001418677 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,780 F1 · shares: Consists of fully vested restricted stock units. Read SEC document |
| October 05, 2017 Filed Oct 6, 2017 23:26 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | GrantCommon Stock | 361 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-056349 · doc4.xml · nonDerivative · entry 1 Barron Hal · CIK 0001418677 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,444 F1 · shares: Consists of fully vested restricted stock units. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 23:47 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | GrantCommon Stock | 516 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-044459 · doc4.xml · nonDerivative · entry 1 Barron Hal · CIK 0001418677 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,083 F1 · shares: Consists of fully vested restricted stock units. Read SEC document |
| June 16, 2017 Filed Jun 19, 2017 20:32 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $23.29 | $0.00 |
DisclosureSEC source: 0001209191-17-040835 · doc4.xml · derivative · entry 1 Barron Hal · CIK 0001418677 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-06-15 F1 · derivative.exercise_date: 100% of the shares subject to the option become vested and exercisable on the earlier of (i) the date of the 2018 Annual Meeting of Stockholders and (ii) the first anniversary of the grant date, in either event, subject to the director continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through such date. Read SEC document |
| April 05, 2017 Filed Apr 6, 2017 20:47 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | GrantCommon Stock | 698 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-026102 · doc4.xml · nonDerivative · entry 1 Barron Hal · CIK 0001418677 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,567 F1 · shares: Consists of fully vested restricted stock units. Read SEC document |
| January 05, 2017 Filed Jan 9, 2017 22:04 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | GrantCommon Stock | 768 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-002963 · doc4.xml · nonDerivative · entry 1 Barron Hal · CIK 0001418677 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,869 F1 · shares: Consists of fully vested restricted stock units. Read SEC document |
| October 05, 2016 Filed Oct 18, 2016 00:37 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | GrantCommon Stock | 438 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-146106 · doc4.xml · nonDerivative · entry 1 Barron Hal · CIK 0001418677 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,101 F1 · shares: Consists of fully vested restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.